168 related articles for article (PubMed ID: 19865824)
21. [Retrobulbar irradiation of endocrine ophthalmopathy: a comparison between 10 and 16 Gy total dose].
Pfluger T; Wendt T; Toroutoglou N; Pickardt C; Wuttge R
Strahlenther Onkol; 1990 Oct; 166(10):673-7. PubMed ID: 2237752
[TBL] [Abstract][Full Text] [Related]
22. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis.
Vannucchi G; Campi I; Covelli D; Dazzi D; Currò N; Simonetta S; Ratiglia R; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2009 Sep; 94(9):3381-6. PubMed ID: 19567525
[TBL] [Abstract][Full Text] [Related]
23. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.
Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Lepri A; Pinchera A
J Endocrinol Invest; 1991 Nov; 14(10):853-60. PubMed ID: 1802923
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of irradiation for patients with progressive Graves' ophthalmopathy.
Marquez SD; Lum BL; McDougall IR; Katkuri S; Levin PS; MacManus M; Donaldson SS
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):766-74. PubMed ID: 11697323
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective study.
Lanzolla G; Menconi F; Nicolì F; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Dec; 44(12):2575-2579. PubMed ID: 33844165
[TBL] [Abstract][Full Text] [Related]
27. Results and prognostic factors in retrobulbar radiotherapy combined with systemic corticosteroids for endocrine orbitopathy (Graves' disease).
Staar S; Müller RP; Hammer M; Nolte M
Front Radiat Ther Oncol; 1997; 30():206-17. PubMed ID: 9205903
[No Abstract] [Full Text] [Related]
28. Orbital irradiation for Graves' ophthalmopathy: Is it safe? A long-term follow-up study.
Wakelkamp IM; Tan H; Saeed P; Schlingemann RO; Verbraak FD; Blank LE; Prummel MF; Wiersinga WM
Ophthalmology; 2004 Aug; 111(8):1557-62. PubMed ID: 15288988
[TBL] [Abstract][Full Text] [Related]
29. Natural history of graves' orbitopathy after treatment.
Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
[TBL] [Abstract][Full Text] [Related]
30. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
31. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
32. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
[TBL] [Abstract][Full Text] [Related]
33. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
Howarth D; Epstein M; Lan L; Tan P; Booker J
Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
[TBL] [Abstract][Full Text] [Related]
34. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
35. Radioiodine therapy for Graves' disease - retrospective analysis of efficacy factors.
Szumowski P; Abdelrazek S; Kociura Sawicka A; Mojsak M; Kostecki J; Sykała M; Myśliwiec J
Endokrynol Pol; 2015; 66(2):126-31. PubMed ID: 25931042
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis of exophthalmos using orbital ultrasonography and treatment of malignant exophthalmos with steroid therapy, orbital radiation therapy, and plasmapheresis.
Yamamoto K; Saito K; Takai T; Yoshida S
Prog Clin Biol Res; 1983; 116():189-205. PubMed ID: 6134291
[TBL] [Abstract][Full Text] [Related]
37. [Corticosteroids and radiotherapy in the treatment of Graves' ophthalmopathy].
Nasr E; Khater S; Nehme-Nasr D; Azoury F; Jambart S
J Med Liban; 2010; 58(2):86-90. PubMed ID: 20549894
[TBL] [Abstract][Full Text] [Related]
38. Radiation therapy for Graves' ophthalmopathy: a retrospective analysis.
Palmer D; Greenberg P; Cornell P; Parker RG
Int J Radiat Oncol Biol Phys; 1987 Dec; 13(12):1815-20. PubMed ID: 3679918
[TBL] [Abstract][Full Text] [Related]
39. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
40. The aftermath of orbital radiotherapy for graves' ophthalmopathy.
Gorman CA; Garrity JA; Fatourechi V; Bahn RS; Petersen IA; Stafford SL; Earle JD; Forbes GS; Kline RW; Buettner H; Robertson DM; Bergstralh EJ; Offord KP; Rademacher DM; Stanley NM; Bartley GB
Ophthalmology; 2002 Nov; 109(11):2100-7. PubMed ID: 12414422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
